Nada Abla

1.2k total citations
23 papers, 401 citations indexed

About

Nada Abla is a scholar working on Computational Theory and Mathematics, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Nada Abla has authored 23 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Computational Theory and Mathematics, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Nada Abla's work include Computational Drug Discovery Methods (8 papers), Malaria Research and Control (7 papers) and Advancements in Transdermal Drug Delivery (5 papers). Nada Abla is often cited by papers focused on Computational Drug Discovery Methods (8 papers), Malaria Research and Control (7 papers) and Advancements in Transdermal Drug Delivery (5 papers). Nada Abla collaborates with scholars based in Switzerland, United Kingdom and United States. Nada Abla's co-authors include Richard H. Guy, Aarti Naik, Yogeshvar N. Kalia, Jennifer Keiser, Michiko Kawamoto, Tsutomu Nakamura, Deanna L. Kroetz, Howard Burt, Travis R. Taylor and Leslie W. Chinn and has published in prestigious journals such as Journal of Controlled Release, Journal of Pharmacology and Experimental Therapeutics and Frontiers in Immunology.

In The Last Decade

Nada Abla

21 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nada Abla Switzerland	13	108	84	72	57	51	23	401
Nikunj Tandel India	10	65 0.6×	96 1.1×	22 0.3×	81 1.4×	25 0.5×	22	330
Misty Saracino United States	15	31 0.3×	250 3.0×	147 2.0×	28 0.5×	311 6.1×	23	729
Barbara Waurzyniak United States	16	16 0.1×	101 1.2×	115 1.6×	51 0.9×	51 1.0×	31	563
Abhishek Kumar India	16	24 0.2×	123 1.5×	35 0.5×	278 4.9×	53 1.0×	30	641
Luke S. S. Guo United States	10	45 0.4×	254 3.0×	16 0.2×	37 0.6×	67 1.3×	13	518
C. Shipman United States	11	80 0.7×	207 2.5×	93 1.3×	29 0.5×	256 5.0×	19	691
Agnès Didier France	8	15 0.1×	132 1.6×	192 2.7×	10 0.2×	21 0.4×	10	350
Richard A. Finley United States	9	26 0.2×	114 1.4×	44 0.6×	18 0.3×	30 0.6×	15	459
Joana Magalhães Portugal	11	101 0.9×	87 1.0×	13 0.2×	11 0.2×	34 0.7×	13	319
Pradeep Sharma India	10	26 0.2×	142 1.7×	68 0.9×	16 0.3×	49 1.0×	37	425

Countries citing papers authored by Nada Abla

Since Specialization

Citations

This map shows the geographic impact of Nada Abla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nada Abla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nada Abla more than expected).

Fields of papers citing papers by Nada Abla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nada Abla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nada Abla. The network helps show where Nada Abla may publish in the future.

Co-authorship network of co-authors of Nada Abla

This figure shows the co-authorship network connecting the top 25 collaborators of Nada Abla. A scholar is included among the top collaborators of Nada Abla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nada Abla. Nada Abla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Almond, Lisa M., Khaled Abduljalil, Amita Pansari, et al.. (2025). PBPK‐Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population. CPT Pharmacometrics & Systems Pharmacology. 14(4). 738–750.

Abla, Nada, et al.. (2025). Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study. Tropical Medicine and Health. 53(1). 116–116.

Abla, Nada, et al.. (2024). PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies. Clinical and Translational Science. 17(7). e13865–e13865. 2 indexed citations

Kuemmerle, Andrea, et al.. (2024). Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin. Clinical and Translational Science. 17(4). e13738–e13738. 2 indexed citations

Abla, Nada, Elodie Jambert, Stephan Duparc, et al.. (2024). Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure. Malaria Journal. 23(1). 287–287. 2 indexed citations

Abla, Nada, Eleanor Howgate, Karen Rowland Yeo, et al.. (2023). Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1335–1346. 13 indexed citations

Chandiwana, Nomathemba, Hilary Johnstone, Chung Ju, et al.. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBioMedicine. 86. 104322–104322. 12 indexed citations

Hewitt, Philip, et al.. (2022). An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2. Toxicology and Applied Pharmacology. 443. 116006–116006. 4 indexed citations

Katneni, Kasiram, Thao Pham, Jessica Saunders, et al.. (2018). Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds. Pharmaceutical Research. 35(11). 210–210. 15 indexed citations

10.

Bonate, Peter L., Tianli Wang, Paul Passier, et al.. (2018). Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. Journal of Pharmacokinetics and Pharmacodynamics. 45(5). 747–762. 19 indexed citations

11.

Abla, Nada, Sridevi Bashyam, Susan A. Charman, et al.. (2017). Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol. ACS Medicinal Chemistry Letters. 8(12). 1304–1308. 11 indexed citations

12.

Abla, Nada, Jennifer Keiser, Mireille Vargas, et al.. (2017). Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model. PLoS neglected tropical diseases. 11(9). e0005942–e0005942. 30 indexed citations

13.

Haselmayer, Philipp, Montserrat Camps, Samer El Bawab, et al.. (2014). Characterization of Novel PI3KÎ´ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Frontiers in Immunology. 5. 233–233. 24 indexed citations

14.

Molette, Jérôme, Nada Abla, Dominique Besson, et al.. (2013). Identification and Optimization of an Aminoalcohol-Carbazole Series with Antimalarial Properties. ACS Medicinal Chemistry Letters. 4(11). 1037–1041. 37 indexed citations

15.

Henchoz, Yveline, Nada Abla, Jean‐Luc Veuthey, & Pierre‐Alain Carrupt. (2009). A fast screening strategy for characterizing peptide delivery by transdermal iontophoresis. Journal of Controlled Release. 137(2). 123–129. 13 indexed citations

16.

Abla, Nada, Leslie W. Chinn, Tsutomu Nakamura, et al.. (2008). The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene. Journal of Pharmacology and Experimental Therapeutics. 325(3). 859–868. 88 indexed citations

17.

Abla, Nada, Aarti Naik, Richard H. Guy, & Yogeshvar N. Kalia. (2006). Topical Iontophoresis of Valaciclovir Hydrochloride Improves Cutaneous Aciclovir Delivery. Pharmaceutical Research. 23(8). 1842–1849. 21 indexed citations

18.

Abla, Nada, Aarti Naik, Richard H. Guy, & Yogeshvar N. Kalia. (2005). Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. Journal of Controlled Release. 108(2-3). 319–330. 34 indexed citations

19.

Abla, Nada, Laurent Geiser, Aarti Naik, et al.. (2005). Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility. Journal of Pharmaceutical Sciences. 94(12). 2667–2675. 17 indexed citations

20.

Abla, Nada, Aarti Naik, Richard H. Guy, & Yogeshvar N. Kalia. (2005). Effect of Charge and Molecular Weight on Transdermal Peptide Delivery by Iontophoresis. Pharmaceutical Research. 22(12). 2069–2078. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact